Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy

Nanoscale ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 611-621 ◽  
Author(s):  
Ya Chang ◽  
Shuo Yao ◽  
Yifang Chen ◽  
Jingjing Huang ◽  
Aihua Wu ◽  
...  

A SHEATH strategy was developed to overcome the delivery barrier against drug development and the clinical application of the cytoplasmic active proteins (e.g., ribosome-inactivating proteins, RIPs).

Author(s):  
Lihini Ranesha Weerakkody ◽  
Сhamindri Witharana

Cancer is the world's second leading cause of death in humans. Conventional anticancer therapies are often associated with lack of tumor specificity, failure to detect small metastases, increased resistance of tumors to anticancer drugs, and unintended adverse effects. Numerous alternative and better strategies in cancer treatment have been developed to overcome the negative effects of traditional cancer therapies. More than a century ago, William Coley, the father of cancer immounotherapy, laid the groundwork for bacterial anticancer therapy. Bacterial immunotherapy has been emerging as a potential anticancer therapy. Moreover, certain obligate and facultative anaerobic bacterial species are exploited as vectors for gene delivery to treat cancer. These genes encode for anticancer agents, cytokines, cytotoxic peptides, anti-angiogenic proteins, therapeutic molecules and prodrug-converting enzymes. Genetically engineered bacterial strains of Salmonella, Bifidobacterium, Clostridium and Listeria are widely used to deliver genes in anticancer therapy since they can selectively accumulate in solid tumors with a hypoxic/necrotic core in vivo, providing appealing delivery systems to target therapeutic agents and immunomodulatory molecules to the site of tumor. Certain genetically modified bacterial species such as Bifidobacterium longum and Bacillus licheniformis have been effectively used for the enzyme/prodrug therapy for cancer. Furthermore, certain anaerobic bacteria are emerging as potential tumor markers due to the increased mobility and the selectivity in germinating and multiplying in hypoxic/anoxic environments. Many of these novel developments have been studied extensively in different experimental models of cancer and certain clinical trials are ongoing for some treatment modalities. Although favourable results have shown so far, further studies and technological innovations are required to ensure the efficacy of bacterial anticancer therapy.


2010 ◽  
Vol 57 (1) ◽  
Author(s):  
Aleksandra Rusin ◽  
Zdzisław Krawczyk ◽  
Grzegorz Grynkiewicz ◽  
Agnieszka Gogler ◽  
Jadwiga Zawisza-Puchałka ◽  
...  

Genistein, the principal isoflavone constituent of soybean, attracts much attention as a natural molecule with significant affinity towards targets of potential medicinal interest, but also as a food supplement or prospective chemopreventive agent. Since its physicochemical properties are considered suboptimal for drug development, much effort has been invested in designing its analogs and conjugates in hope to obtain compounds with improved efficacy and selectivity. The aim of this article is to summarize current knowledge about the properties of synthetic genistein derivatives and to discuss possible clinical application of selected novel compounds. Some basic information concerning chemical reactivity of genistein, relevant to the synthesis of its derivatives, is also presented.


2020 ◽  
Vol 107 ◽  
pp. 110285 ◽  
Author(s):  
Piyush Kumar Gupta ◽  
Surya Kant Tripathi ◽  
Sreenath Pappuru ◽  
Siva Chander Chabattula ◽  
Kavitha Govarthanan ◽  
...  

2018 ◽  
Vol 19 (7) ◽  
pp. 1875 ◽  
Author(s):  
Qi Hui ◽  
Zi Jin ◽  
Xiaokun Li ◽  
Changxiao Liu ◽  
Xiaojie Wang

1994 ◽  
Vol 16 (2) ◽  
pp. 163
Author(s):  
J. Schlom ◽  
P. Hand ◽  
D. Slavin-Chiorini ◽  
J. Greiner ◽  
P. Schott ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document